Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review.

about

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review.

Item

http://www.wikidata.org/entity/Q47121307

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Molecular targeted agents as s ...... a: a meta-analysis and review.

@en

Molecular targeted agents as s ...... a: a meta-analysis and review.

@nl

type

Item

label

Molecular targeted agents as s ...... a: a meta-analysis and review.

@en

Molecular targeted agents as s ...... a: a meta-analysis and review.

@nl

prefLabel

Molecular targeted agents as s ...... a: a meta-analysis and review.

@en

Molecular targeted agents as s ...... a: a meta-analysis and review.

@nl

P1476

Molecular targeted agents as s ...... a: a meta-analysis and review.

@en

P2093

Bum Jun Kim

http://www.w3.org/2001/XMLSchema#string

Hyun Joo Jang

http://www.w3.org/2001/XMLSchema#string

Jin Lee

http://www.w3.org/2001/XMLSchema#string

Jung Han Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Sorafenib in advanced hepatocellular carcinoma

Cancer statistics, 2016

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014

Systemic therapy for advanced hepatocellular carcinoma: an update.

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.

P304

102321-102327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21454

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29254247

http://www.w3.org/2001/XMLSchema#string

P932

5731957

http://www.w3.org/2001/XMLSchema#string